- Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate CancerDr. Pedro Barata and Dr. Johann De Bono open the discussion by reviewing the evolving role of radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC) and outlining how these…onclive · 2mo ago↗ source
- FDA’s leadership void leaves biotech with renewed ‘uncertainty’Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted policies with an unclear future.BioPharma Dive · 2mo ago↗ source
- Dr Bockorny on the Rationale for Targeting CCR8 in Solid TumorsBruno B. Bockorny, MD, discusses the rationale for evaluating the anti-CCR8 antibody in a phase 1 trial in solid tumors.onclive